Skip to main content
. Author manuscript; available in PMC: 2020 Jul 14.
Published in final edited form as: Cell. 2016 Sep 15;167(1):171–186.e15. doi: 10.1016/j.cell.2016.08.057

Figure 1. ER-HoxA9 Cells Undergo Conditional Myeloid Differentiation.

Figure 1.

(A) Primary murine bone marrow cells transduced with MSCVneo-ER-HoxA9 grow as lineage-negative cells in the presence of beta-estradiol, (+) E2. Removal of E2 and inactivation of ER-HoxA9 result in the synchronous upregulation of the myeloid differentiation markers CD11b and Gr-1, as demonstrated by flow cytometry.

(B) Terminal differentiation of the ER-HoxA9 cells is accompanied by exit from the cell cycle.

(C) Morphologic changes that accompany myeloid differentiation are confirmed by Wright-Giemsa staining of cells in the presence and absence of E2.

(D) Terminally differentiated cells, but not undifferentiated cells, are capable of phagocytosis of fluorescently labeled E. coli.

(E-G) In (E), Lys-GFP-ER-HoxA9 cells demonstrate expected changes in myeloid gene expression over a 5-day differentiation time course. Their stepwise gene expression parallels the patterns of unmanipulated murine bone marrow myeloid cells (F) as well as purified populations of primary human bone marrow cells (G). HSC, hematopoietic stem cell; CMP, common myeloid progenitor; GMP, granulocyte-monocyte progenitor; GRAN, granulocytes.

See also Figure S1.